RxDoctor Payments Data

Sanjay Rathi, MD

Neurological Surgery · North Haven, CTNPI 1821007972

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $405,770 of the $540,826 with a category attached, or 75.0%. 56 manufacturers reported payments, led by AbbVie at 37.2% of the total. Among neurological surgery clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$540,826in general payments, 2019–2025

Across 1,277 payments — averaging $423.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$201K
  • EMD Serono, Inc.$196K
  • Neurocrine Biosciences, Inc.$64K
  • Amneal Pharmaceuticals LLC$24K
  • Axsome Therapeutics, Inc.$10K
  • Kyowa Kirin, Inc.$8K
  • plus $38K from 50 others

What the payments were for

  • Consulting fees$40,8058%
  • Speaking & faculty fees$405,77075%
  • Travel & lodging$41,4128%
  • Food & beverage$49,7649%
  • Education$3,0761%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)383$201,255
EMD Serono, Inc.332$195,824
Neurocrine Biosciences, Inc.85$63,665
Amneal Pharmaceuticals LLC50$23,997
Axsome Therapeutics, Inc.8$10,229
Kyowa Kirin, Inc.20$7,720
Bristol Myers Squibb51$7,334
E.r. Squibb & Sons, L.L.C.15$7,214
Sanofi14$4,451
Novartis67$2,836
Amgen(2 entities)22$1,346
Biogen24$1,243
Lundbeck LLC27$949
Genentech, Inc.11$893
Eisai Inc.13$876
SK Life Science, Inc.8$860
Teva Pharmaceuticals USA, Inc.8$781
Genentech USA, Inc.12$777
Johnson & Johnson7$604
MDD US Operations, LLC9$577
UCB, Inc.8$546
Mallinckrodt Hospital Products Inc.15$514
TG Therapeutics, Inc.4$512
Neurelis, Inc.8$474
Argenx US, Inc.4$402
Biohaven Pharmaceuticals, Inc.8$392
Ipsen Biopharmaceuticals, Inc11$387
Jazz Pharmaceuticals Inc.3$369
Alnylam Pharmaceuticals Inc.3$321
Lilly USA, LLC3$274
Abbott2$263
Otsuka America Pharmaceutical, Inc.2$250
Acadia Pharmaceuticals Inc3$224
Sumitomo Pharma America, Inc.2$143
Merz Pharmaceuticals, LLC2$140
ANI Pharmaceuticals, Inc.2$140
Biohaven Pharmaceutical Holding Company Ltd.2$139
Vanda Pharmaceuticals Inc.1$125
AstraZeneca1$125
Impel Pharmaceuticals Inc.1$125
Sunovion Pharmaceuticals Inc.3$125
Avanir Pharmaceuticals, Inc.1$124
Amylyx Pharmaceuticals, Inc.1$122
Akcea Therapeutics, Inc.1$120
Avadel CNS Pharmaceuticals, LLC1$119
Pfizer2$118
Acorda Therapeutics, Inc1$115
Grifols USA, LLC1$96
Promius Pharma LLC1$94
Medtronic1$94
Sanofi-aventis U.S. LLC1$92
Cycle Pharmaceuticals Inc1$80
Supernus Pharmaceuticals, Inc.4$66
Adamas Pharmaceuticals, Inc.1$64
Strongbridge US Inc.4$62
Xeris Pharmaceuticals, Inc.2$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$540,826 in reported general payments places this provider in the 95th percentile of 94 neurological surgery providers in Connecticut.

See all neurological surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$137,617
Medicare patients
71
Services billed
17,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate38$190,616
IngrezzaValbenazine Tosylate14$119,875
RytaryCarbidopa/Levodopa101$102,502
BotoxOnabotulinumtoxina81$100,291
GocovriAmantadine Hcl23$87,724
NourianzIstradefylline24$81,086
CopaxoneGlatiramer Acetate13$74,599
OngentysOpicapone78$59,733
UbrelvyUbrogepant19$41,991
Aimovig AutoinjectorErenumab-Aooe23$18,548
AptiomEslicarbazepine Acetate13$15,169
QuviviqDaridorexant Hcl24$11,668
Rasagiline Mesylate57$11,319
Gabapentin33$1,169
Quetiapine Fumarate52$1,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$224$190,61638 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$63,665$179,60892 claims
AbbVieBotox, Ubrelvy$201,255$142,282100 claims
Amneal Pharmaceuticals LLCRytary$23,997$102,502101 claims
MDD US Operations, LLCGocovri$577$87,72423 claims
Kyowa Kirin, Inc.Nourianz$7,720$81,08624 claims
Teva Pharmaceuticals USA, Inc.Copaxone$781$74,59913 claims
Sunovion Pharmaceuticals Inc.Aptiom$125$15,16913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 94 neurological surgery providers in Connecticut.

Other neurological surgery in North Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →